Prospetive Study Of Thalidomide Maintenance Therapy In High-Risk Diffuse Large B-Cell Lymphoma.

e19551 Background: Patients with high-risk diffuse large B-Cell lymphoma (DLBCL) have a unfavourable clinical outcome even treated with R-CHOP. Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities.This study aimed to explore the efficacy and the tolerability of thalidomide maintenance treatment in patients with high-risk DLBCL. Methods: Patients diagnosised as DLBCL with IPI≥2, aged ≥18 year-old, who achieved completed remission after induction therapy ,with full liver , kidney and bone-marrow function, were eligible for this study. Patients were assigned to receive thalidomide (100 mg/day, increased by 100 mg every 3 days to a maximum of 300 mg/day and aspirin 100 mg/day ) maintenance treatment for two years or observation.Primary endpoint was progression free survival (PFS) .Secondary endpoints were overall survival (OS) and safety. Results: From January 2009 to June 2013, 90 patients were enrolled in this study.30 patients were assigned to thalidomide maintenance treatment a...